Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-10-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the effectiveness of prazosin in treating post-traumatic stress disorder caused by noncombat trauma in individuals taking selective serotonin reuptake inhibitors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance

NCT00108420

Stress Disorder, Post-Traumatic

COMPLETED PHASE4

Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance

NCT00202449

Stress Disorders, Post-Traumatic Sleep Disorders

TERMINATED NA

Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)

NCT00990106

Stress Disorders, Post-Traumatic Combat Disorders Sleep Disorders

COMPLETED NA

Feasibility Study: The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD

NCT00174551

Stress Disorders, Post-Traumatic

UNKNOWN NA

Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD

NCT00532493

PTSD Sleep Disorders

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Post-traumatic stress disorder (PTSD) is an anxiety disorder that can develop after exposure to a terrifying event in which grave physical harm occurred or was threatened. People with PTSD have persistent frightening thoughts and memories of their past ordeal and often feel emotionally numb, especially with people to whom they were once close. PTSD was first recognized in male combat veterans. Today, however, the majority of people who have PTSD are young women who have experienced non combat-related trauma, such as sexual or physical assault or a life-threatening illness or accident. The disorder can be short-lived, but PTSD can also become chronic, with long lasting symptoms that are often treatment-resistant, possibly causing severe functional disability. Frequent trauma-related nightmares and other debilitating sleep disruptions are examples of chronic PTSD symptoms for which an effective treatment has not been developed. Sertraline and paroxetine, both selective serotonin reuptake inhibitors (SSRIs), are the only drugs approved by the FDA for treating PTSD. Neither of them, however, has been effective in reducing PTSD-related sleep disruption. Studies have shown that the drug prazosin has been effective in reducing distressing trauma-related nightmares in older male combat veterans. This study will evaluate the effectiveness of prazosin in treating post-traumatic stress disorder caused by noncombat trauma in individuals already being treated with SSRIs.

Participants in this double-blind study will first undergo 12 weeks of treatment with psychotherapy and a standard SSRI. After 12 weeks, participants will be randomly assigned to receive either prazosin or placebo in addition to psychotherapy and standard SSRI treatment for a total of 8 weeks. Study visits will occur weekly for the first 12 weeks, and then at Weeks 1, 2, 4, 6, and 8 during the 8-week phase. Additionally, follow-up visits will be held 4 and 18 weeks post-intervention. PTSD symptoms, disorder severity, and frequency of sleep disturbances will be assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-Traumatic Stress Disorder Sleep Initiation and Maintenance Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Participants will receive treatment with prazosin plus psychotherapy

Group Type EXPERIMENTAL

Prazosin

Intervention Type DRUG

Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.

Psychotherapy

Intervention Type BEHAVIORAL

All participants will undergo psychotherapy during medication treatment period.

2

Participants will receive treatment with placebo plus psychotherapy

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo capsules are taken orally twice per day at 10 am and bedtime.

Psychotherapy

Intervention Type BEHAVIORAL

All participants will undergo psychotherapy during medication treatment period.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prazosin

Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.

Intervention Type DRUG

Placebo

Placebo capsules are taken orally twice per day at 10 am and bedtime.

Intervention Type DRUG

Psychotherapy

All participants will undergo psychotherapy during medication treatment period.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Minipress

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of PTSD, as derived from the Clinician-Administered PTSD Scale (CAPS)
* Stabilized on any necessary medications for at least 4 weeks prior to study entry
* Score of greater than 4 on the CAPS Recurrent Distressing Dreams item (maximum score of 8)
* Score of greater than 4 on the CAPS Difficulty Falling or Staying Asleep item (maximum score of 8)
* Agrees to use an effective form of contraception throughout the study

Exclusion Criteria

* Any acute or significant chronic medical illness
* Any unstable medical condition
* Unstable angina, recent heart attack, history of congestive heart failure, pre-existing hypotension (systolic blood pressure less than 110 mm Hg), or orthostatic hypotension
* Insulin-dependent diabetes
* Chronic kidney or liver failure
* Pancreatitis or gout
* Meniere's disease, benign positional vertigo, or narcolepsy
* Allergy or previous adverse reaction to prazosin or other alpha-1 antagonist
* Currently taking another alpha-1 antagonist agent
* Pregnant
* DSM-IV diagnosis of cognitive disorder, schizophrenia, schizoaffective disorder, bipolar disorder, or other psychotic disorder
* Current delirium
* Active substance dependence disorder within 3 months of study entry
* Current substance use other than alcohol (no more than 2 drinks per day)
* Severe psychiatric instability or situational life crises, including evidence of suicidal or homicidal ideation
* Currently taking any other psychotropic medication (e.g., antidepressants, benzodiazepines, anti-convulsants, anti-psychotics, sedating antihistamines, sedatives/hypnotics (exclusionary medications will be discontinued and participants will undergo a 2-week washout period before baseline assessments)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No